A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 / Egeler, M.d., Van Leeuwen, M., Fraterman, I., Van Den Heuvel, N., Boekhout, A.h., Lai-Kwon, J., Wilthagen, E.a., Eriksson, H., Haanen, J.b., Wilgenhof, S., Ascierto, P.a., Van Akkooi, A., van de Poll-Franse, L.v.. - In: MOLECULAR THERAPY. - ISSN 1525-0016. - (2023). [10.1016/j.ymthe.2022.12.017]

A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19

Ascierto PA;
2023

2023
A first-in-human trial on the safety and immunogenicity of COVID-eVax, a cellular response-skewed DNA vaccine against COVID-19 / Egeler, M.d., Van Leeuwen, M., Fraterman, I., Van Den Heuvel, N., Boekhout, A.h., Lai-Kwon, J., Wilthagen, E.a., Eriksson, H., Haanen, J.b., Wilgenhof, S., Ascierto, P.a., Van Akkooi, A., van de Poll-Franse, L.v.. - In: MOLECULAR THERAPY. - ISSN 1525-0016. - (2023). [10.1016/j.ymthe.2022.12.017]
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11588/1020351
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 18
  • ???jsp.display-item.citation.isi??? ND
social impact